Product Images Tadalafil
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Tadalafil NDC 50436-0372 by Unit Dose Services, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a description of a medication called Tadalafil, with a strength of 20 mg and 6 tablets called Migby. It was produced by Inas Pharm Limited in India and its NDC is 50436-0372-2. The medication should be stored at room temperature and kept out of reach of children. The serial number is 3000001042 and the lot number is X000. The text also includes three different NDC codes and their associated drug and lot numbers.*
This is a description of the plasma tadalafil concentration in micrograms per liter (ug/L) over time at different doses of tadalafil. The graph shows four lines representing different dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg doses for five consecutive days. The x-axis shows time in hours, and the y-axis shows the plasma tadalafil concentration. There is a gradual increase in concentration after each dose, with the once-daily 5-mg dose following 5 consecutive days of administration showing the highest and most sustained concentration over time.*
The text provides a figure or graph showing the change in the International Prostate Symptom Score (IPSS) total score over time in weeks for individuals who used Tadalafil and Placebo. The graph shows that Tadalafil had a significant effect in reducing the IPSS total score compared to Placebo. The study lasted for 12 weeks.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.